Intensive insulin therapy does not alter the inflammatory response in patients undergoing coronary artery bypass graft (CABG): a randomized controlled trial
Completed
- Conditions
- Coronary artery bypass graftCirculatory System
- Registration Number
- ISRCTN95608630
- Lead Sponsor
- Radboud University Nijmegen Medical Centre (The Netherlands)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
1. Adults, after uncomplicated CABG
2. Non-diabetics
Exclusion Criteria
1. Diabetes
2. Renal failure
3. Use of anti-inflammatory drugs
4. Recent myocardial ischemia
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular pathways link intensive insulin therapy to inflammatory response modulation in CABG patients?
How does intensive insulin therapy compare to standard glycemic control in reducing post-CABG inflammation markers like IL-6 and CRP?
Are specific biomarkers such as hs-CRP or TNF-α predictive of differential response to intensive insulin in coronary artery bypass surgery?
What adverse events are associated with intensive insulin protocols in cardiac surgery, and how are they managed compared to conventional therapy?
How do combination approaches of insulin with anti-inflammatory agents like metformin or statins affect CABG outcomes in glycemic control studies?